Moderna (MRNA) Accounts Payables (2017 - 2026)

Moderna (MRNA) has 10 years of Accounts Payables data on file, last reported at $161.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 28.76% year-over-year to $161.0 million in Q1 2026; TTM through Mar 2026 was $161.0 million, a 28.76% decrease from a year earlier, with the FY2025 full-year figure at $317.0 million, down 21.73% from the prior year.
• Accounts Payables for Q1 2026 stood at $161.0 million, down from $317.0 million in the prior quarter.
• Over the last five years, Accounts Payables for MRNA reached as high as $520.0 million in Q4 2023 and fell as low as $161.0 million in Q1 2026.
• Historically, Accounts Payables has averaged $311.5 million across 5 years, with a median of $310.0 million in 2023.
• Across the five-year window, Accounts Payables jumped 2387.5% in 2022 and plunged 52.96% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $487.0 million in 2022, then gained by 6.78% to $520.0 million in 2023, then dropped by 22.12% to $405.0 million in 2024, then retreated by 21.73% to $317.0 million in 2025, then sank by 49.21% to $161.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $161.0 million in Q1 2026, $317.0 million in Q4 2025, and $267.0 million in Q3 2025.